Hudson Bay Capital Management
NMRA icon

Hudson Bay Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Hudson Bay Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,449
Closed -$16.5K – 1549
2025
Q2 		$16.5K Buy
+22,449
New +$17K ﹤0.01% 1319
2024
Q2 		– Sell
-98,300
Closed -$1.35M – 886
2024
Q1 		$1.35M Buy
+98,300
New +$1.59M 0.01% 516

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Hudson Bay Capital Management's NMRA Position: Q3 2025 in Review

Hudson Bay Capital Management sold out of Neumora Therapeutics (NMRA) in Q3 2025, closing a stake of 22,449 shares — an estimated $16.5K sold.

Hudson Bay Capital Management first reported a position in NMRA in Q1 2024 and held it in 2 quarters. The position peaked at $1.35M in Q1 2024. 93 funds tracked by Wall St. Rank hold NMRA as of Q3 2025.

  • Hudson Bay Capital Management reported no remaining Neumora Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 22,449 Neumora Therapeutics shares in Q3 2025, an estimated $16.5K.
  • Hudson Bay Capital Management first reported a position in Neumora Therapeutics in Q1 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Neumora Therapeutics position peaked at $1.35M in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2025.

Based on Hudson Bay Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.